How much to invest in glycemic control of a patient with diabetes mellitus type 2? A constant dilemma for the Brazilian Public Health System (SUS)

• Main Authors: Ana Carolina de Oliveira Gonçalves, Maurilio de Souza Cazarim, Cristina Sanches, Leonardo Régis Leira Pereira, André de Oliveira Baldoni
• Format: Article
• Language: English
• Published: Universidade de São Paulo
• Series: Brazilian Journal of Pharmaceutical Sciences
• Subjects: Diabetes mellitus; Pharmacoeconomics; Health care cost
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100522&lng=en&tlng=en

Diabetes mellitus type 2 (DM2) affects millions of people worldwide and causes several complications for the patient, consuming large sums of financial resources from the health services. This study aims to estimate the financial investment of DM2 treatment for glycemic control of the patient, from the point of view of the municipal Public Health System (SUS). The Delphi technique was used to validate the opinion of a team of judges, specialists in DM2, and health service managers, on the investment necessary for glycemic control of patients with DM2 through the application of questionnaires. In order for the patient to achieve glycated hemoglobin (A1c) < 7%, an investment of US$ 2,419.06 (value/patient/year) is necessary. As the value of A1c increases, investment is reduced. This result reveals the intention to allocate resources for the prevention of DM2 and its complications.